AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
Rhea-AI Summary
Positive
- Chairman's increased stake signals confidence in company's future
- Significant insider ownership with Chairman holding over 6.5 million shares
- Open market purchase demonstrates management's alignment with shareholder interests
Negative
- None.
News Market Reaction
On the day this news was published, ACUT declined 7.34%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. This brings his total holding to 6,502,400 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
How many ACUT shares did AccuStem Sciences Chairman purchase in June 2025?
What is the total number of shares held by AccuStem Sciences Chairman Gabriele Cerrone?
What does the Chairman's share purchase indicate about AccuStem Sciences (ACUT)?
What type of company is AccuStem Sciences (ACUT)?
